查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2071524

非小細胞肺癌（NSCLC）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

Non-Small Cell Lung Cancer (NSCLC) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 155 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 法國非小細胞肺癌 (NSCLC) 市場預計將從 2025 年的 13 億美元成長到 2035 年的 32 億美元，這表明在癌症治療創新的推動下，市場正在強勁擴張。
  • 以下因素正在推動市場成長：
  • 高價分子標靶療法和免疫療法的應用日益增加。
  • 擴大基於生物標記的治療適應症範圍，並推廣個人化醫療方法。
  • 由於存活率的提高，治療持續時間正在延長。
  • 市場規模的成長得益於新一代抗癌藥物的不斷推出和聯合療法的日益普及。
  • 由新型標靶治療、抗體藥物複合體(ADC) 和下一代查核點抑制劑組成的強大研發管線有望帶來巨大的商業性機會。
  • 未來的成長取決於早期檢測的進展、克服治療抗藥性的進展以及提高進行性或轉移性非小細胞肺癌 (NSCLC) 患者的長期存活率。

非小細胞肺癌（NSCLC）概述

非小細胞肺癌（NSCLC）是最常見的肺癌類型，約佔所有肺癌病例的85%。約15%至20%的患者在早期確診，此時手術切除合併輔助化療或放射線治療通常是最佳的治癒機會。風險因素可分為可改變因素和不可改變因素。可改變風險因素包括吸煙、被動吸煙以及職業或環境暴露於石棉、氡、砷、鉻、鎳、電離輻射和多環芳烴。不可改變風險因素包括年齡、家族病史和遺傳易感性。此外，過去曾接受過胸部放射治療（例如治療乳癌或何傑金氏淋巴瘤等惡性腫瘤）也會增加日後罹患NSCLC的風險。

主要亮點

  • 在德國，經生存調整後的非小細胞肺癌 (NSCLC) 患者人數預計將從 2025 年的 497,473 人增加到 2035 年的 532,039 人，這反映了生存率的提高和疾病負擔的加重。
  • 非小細胞肺癌仍然是最常見的肺癌亞型，佔全球肺癌診斷和死亡病例的大多數。
  • 隨著分子診斷和生物標記檢測技術的日益普及，精準腫瘤學方法在德國的應用也越來越廣泛。
  • 治療模式已顯著轉向標靶治療和免疫腫瘤藥物，從而提高了無惡化生存期和總存活期。
  • 在抗藥性突變、晚期診斷、轉移性疾病進展和治療順序最佳化方面仍存在未滿足的需求。
  • 隨著對標靶 KRAS、EGFR、ALK、HER2 和 PD-(L)1 的療法的關注度不斷提高，預計在預測期內競爭格局將進一步發生變化。

格式化和更新訊息

  • 詳細報告（PDF）
  • 市場預測模型（基於微軟Excel）
  • 流行病學數據（MS Excel，互動式工具）
  • 高階主管洞察（PPT簡報）
  • 其他功能：定期更新、自訂和顧問支援。
  • 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

  • 如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
  • 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
  • 未來十年市場收入和病患佔有率的預測是多少？
  • 哪些因素對市場趨勢影響最大？
  • 受訪專家對目前和新興的治療方法有何看法？
  • 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
  • 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
  • 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • Pfizer
  • Merck Sharp &Dohme LLC
  • AstraZeneca
  • GlaxoSmithKline
  • BeiGene
  • Arcus Biosciences, Inc.
  • AbbVie
  • STCube, Inc.
  • Avistone Biotechnology Co., Ltd.
  • Regeneron Pharmaceuticals
  • Suzhou Zelgen Biopharmaceuticals Co., Ltd.
  • Daiichi Sankyo
  • Akeso
  • Bristol-Myers Squibb
  • RemeGen Co., Ltd.
  • BioNTech SE
  • Hoffmann-La Roche
  • Nuvation Bio Inc.
  • TJ Biopharma Co., Ltd.
  • Klus Pharma Inc.
  • Henan Genuine Biotech Co., Ltd.
  • Gilead Sciences
  • Genentech, Inc.
  • Revolution Medicines, Inc.
  • Servier Bio-Innovation LLC
  • Summit Therapeutics
  • Chipscreen Biosciences, Ltd.
  • Eli Lilly and Company
  • Integro Theranostics
  • Amgen
  • Tango Therapeutics, Inc.
  • Verastem, Inc.
  • Nuvalent Inc.
  • ArriVent BioPharma, Inc.
  • IO Biotech
  • Betta Pharmaceuticals Co., Ltd.
  • Replimune, Inc.
  • ImmunityBio, Inc.

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業利益與風險等。

第2章：疾病背景

  • 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

  • 重點
  • 發病率/盛行率
  • 已確診並正在接受藥物治療的患者族群。
  • 合併症
  • 其他相關患者群

第4章 市場規模及預測

  • 重點
  • 市場促進因素與限制因素
  • 按藥物類別分類的趨勢
  • 各國具體趨勢

第5章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 目前主要療法－概述及關鍵意見領袖見解
  • 新興療法
  • 重點
  • 值得關注的後期新興療法—概述、市場上市預期和關鍵意見領袖見解
  • 值得關注的早期研發管線

第6章：未滿足的需求與目標產品分析

  • 尚未滿足的主要需求及其透過新興療法實現的潛力。
  • TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

簡介目錄

Non-Small Cell Lung Cancer (NSCLC) Market Outlook

Thelansis's "Non-Small Cell Lung Cancer (NSCLC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Small Cell Lung Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Non-Small Cell Lung Cancer (NSCLC) Overview

Non-small cell lung cancer (NSCLC) is the predominant form of lung cancer, accounting for approximately 85% of all cases. Around 15-20% are diagnosed at an early stage, where surgical resection, often combined with adjuvant chemotherapy or radiotherapy, offers the best chance of cure. Risk factors can be divided into modifiable and non-modifiable categories. Modifiable risks include tobacco smoking, secondhand smoke, and occupational or environmental exposures such as asbestos, radon, arsenic, chromium, nickel, ionizing radiation, and polycyclic aromatic hydrocarbons. Non-modifiable risks include age, family history, and genetic predisposition. Additionally, prior chest irradiation for malignancies such as breast cancer or Hodgkin lymphoma increases the likelihood of developing NSCLC later in life.

Key Highlights

  • In Germany, survival-adjusted prevalent cases of Non-Small Cell Lung Cancer (NSCLC) are projected to increase from 497,473 patients in 2025 to 532,039 patients by 2035, reflecting improved survival outcomes and growing disease burden.
  • NSCLC remains the most common subtype of lung cancer, accounting for the majority of lung cancer diagnoses and mortality worldwide.
  • Increasing adoption of molecular diagnostics and biomarker testing is enabling broader use of precision oncology approaches in Germany.
  • Treatment paradigm has significantly shifted toward targeted therapies and immuno-oncology agents, improving progression-free and overall survival outcomes.
  • Persistent unmet need exists in resistant mutations, late-stage diagnosis, metastatic disease progression, and treatment sequencing optimization.
  • Growing focus on KRAS, EGFR, ALK, HER2, and PD-(L)1 targeted therapies is expected to further transform the competitive landscape over the forecast period.

Market Overview

  • The France NSCLC market is projected to grow from USD 1.3 billion in 2025 to USD 3.2 billion by 2035, indicating strong market expansion driven by innovation in oncology therapeutics.
  • Market growth is driven by:
  • Rising adoption of premium-priced targeted therapies and immunotherapies
  • Increasing biomarker-driven treatment eligibility and personalized medicine approaches
  • Improved survival rates leading to longer treatment duration
  • Market value is supported by continuous launch of next-generation oncology agents and expanding utilization of combination treatment regimens.
  • A robust pipeline of novel targeted therapies, antibody-drug conjugates (ADCs), and next-generation checkpoint inhibitors is expected to create significant commercial opportunities.
  • Future growth will depend on advancements in early detection, overcoming therapeutic resistance, and improving long-term survival in advanced and metastatic NSCLC patients.

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • Pfizer
  • Merck Sharp & Dohme LLC
  • AstraZeneca
  • GlaxoSmithKline
  • BeiGene
  • Arcus Biosciences, Inc.
  • AbbVie
  • STCube, Inc.
  • Avistone Biotechnology Co., Ltd.
  • Regeneron Pharmaceuticals
  • Suzhou Zelgen Biopharmaceuticals Co., Ltd.
  • Daiichi Sankyo
  • Akeso
  • Bristol-Myers Squibb
  • RemeGen Co., Ltd.
  • BioNTech SE
  • Hoffmann-La Roche
  • Nuvation Bio Inc.
  • TJ Biopharma Co., Ltd.
  • Klus Pharma Inc.
  • Henan Genuine Biotech Co., Ltd.
  • Gilead Sciences
  • Genentech, Inc.
  • Revolution Medicines, Inc.
  • Servier Bio-Innovation LLC
  • Summit Therapeutics
  • Chipscreen Biosciences, Ltd.
  • Eli Lilly and Company
  • Integro Theranostics
  • Amgen
  • Tango Therapeutics, Inc.
  • Verastem, Inc.
  • Nuvalent Inc.
  • ArriVent BioPharma, Inc.
  • IO Biotech
  • Betta Pharmaceuticals Co., Ltd.
  • Replimune, Inc.
  • ImmunityBio, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)